Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.63 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.60 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.60 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.56 |
| ▸ | RRM1 | P23921 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2863618 | 1.00 | EPHX1 (0.63) | EPHX1GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL20192908 | 0.88 | DPP7 (0.49) | EPHX1GNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL10615527 | 0.86 | GRIK1 (0.57) | GNAI3GNAO1GNAI1DPP7NOD1 | |
| SCHEMBL4385896 | 0.86 | GRIK1 (0.57) | GNAI3GNAO1GNAI1DPP7NOD1 | |
| SCHEMBL1243678 | 0.86 | NOD1 (0.74) | GNAI3GNAO1GNAI1DPP7NOD1 | |
| SCHEMBL17392871 | 0.86 | NOD1 (0.74) | GNAI3GNAO1GNAI1DPP7NOD1 | |
| SCHEMBL308741 | 0.86 | NOD1 (0.74) | GNAI3GNAO1GNAI1DPP7NOD1 | |
| SCHEMBL15986104 | 0.86 | NOD1 (0.74) | GNAI3GNAO1GNAI1DPP7NOD1 | |
| SCHEMBL2386271 | 0.86 | NOD1 (0.74) | GNAI3GNAO1GNAI1DPP7NOD1 | |
| SCHEMBL13855547 | 0.86 | NOD1 (0.74) | GNAI3GNAO1GNAI1DPP7NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0725057-B1 | Alkylsulfonyl or alkylaminocarbonyl substituted lysine derivatives, process for their preparation, their use especially in cosmetics and compositions containing them | OREAL (FR) | 1997-01-15 | — | — | EP | claimed |
| EP-0725057-A1 | Alkylsulfonyl or alkylaminocarbonyl substituted lysine derivatives, process for their preparation, their use especially in cosmetics and compositions containing them | L'OREAL (FR) | 1996-08-07 | — | — | EP | claimed |
| EP-4681719-A2 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX Therapeutics Inc. (CA) | 2026-01-21 | — | — | EP | disclosed |
| EP-3915565-B1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX THERAPEUTICS INC (CA) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024033705-A1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX THERAPEUTICS, INC. (CA) | 2024-02-15 | — | — | WO | disclosed |
| US-20230134136-A1 | METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES | XORTX THERAPEUTICS, INC. (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230082788-A1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX THERAPEUTICS, INC. (CA) | 2023-03-16 | — | — | US | disclosed |
| CN-115697383-A | Methods of treating viral infections and health problems | 艾伦·戴维多夫 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121099-A2 | METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES | Davidoff, Allen (CA) | 2023-01-25 | — | — | EP | disclosed |
| US-11406713-B2 | Xanthine oxidase inhibitor formulations | XORTX THERAPEUTICS, INC. (CA) | 2022-08-09 | — | — | US | disclosed |
| EP-3915565-A2 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX Therapeutics Inc. (CA) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021186250-A2 | METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES | DAVIDOFF ALLEN (CA) | 2021-09-23 | — | — | WO | disclosed |
| EP-3001814-B1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | ALLEN DAVIDOFF (CA) | 2021-05-19 | — | — | EP | disclosed |
| EP-3001814-A2 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | Allen, Davidoff (CA) | 2016-04-06 | — | — | EP | disclosed |
| US-20160038595-A1 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | XORTX THERAPEUTICS, INC. (CA) | 2016-02-11 | — | — | US | disclosed |
| WO-2014140868-A2 | XANTHINE OXIDASE INHIBITOR FORMULATIONS | ALLEN DAVIDOFF (CA) | 2014-09-18 | — | — | WO | disclosed |
| EP-0725057-B1 | Alkylsulfonyl or alkylaminocarbonyl substituted lysine derivatives, process for their preparation, their use especially in cosmetics and compositions containing them | OREAL (FR) | 1997-01-15 | — | — | EP | disclosed |
| EP-0725057-A1 | Alkylsulfonyl or alkylaminocarbonyl substituted lysine derivatives, process for their preparation, their use especially in cosmetics and compositions containing them | L'OREAL (FR) | 1996-08-07 | — | — | EP | disclosed |